Comprehensive Library Of Resveratrol News

“Molecular biologists are taking backward steps in calling for scientific studies that have already taken place.  They are asking for scientific ground to be covered that has already been covered.”

Those are the terse words of Bill Sardi, managing partner for LONGEVINEX®, the world’s best tested resveratrol pill, in sharply written responses to recently published scientific reports calling for further study of red wine resveratrol pills.

“Molecular biologists are calling for research to be conducted with resveratrol pills that represent two steps backwards.  Specifically they are calling for advanced encapsulation technology and studies comparing resveratrol to a calorie restricted diet, both which have already been achieved by Longevinex®, Sardi emphasizes.

For example, researchers reporting the Annals of the New York Academy of Sciences call for further research into encapsulation methods to stabilize and improve the bioavailability of resveratrol (rez-vair-ah-trol), a red wine molecule known for its anti-aging properties.

Sardi’s strongly-worded email was dispatched in reply to a call for more studies.

To: Mary Ann Augustin July 20, 2013
CSIRO
Commonwealth Scientific and Industrial Research Organization(CSIRO)
(Australia’s government body for scientific research)
Preventative Health National Research Flagship and CSIRO Animal, Food and Health Sciences, Werribee, Victoria, Australia.

Re: Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol.  Annals N.Y. Acad. Sci. 1290 (2013) 107–112

We wish to inform you our company has produced and distributed a micro encapsulated, micronized resveratrol-based dietary supplement (Longevinex®) since 2004 and was the first to commercially stabilize resveratrol.

Furthermore, we wish to inform you:

1. Our product has recently undergone toxicity testing that would meet requirements as a new dietary ingredient in the USA.
2. Unlike plain resveratrol, Longevinex® uniquely exhibits no cytotoxicity in mega-doses and does not exhibit the anticipated U-shaped risk curve where high-dose resveratrol becomes a pro-oxidant. Longevinex® is the first matrix in biology to exhibit an L-shaped risk curve.
3. Longevinex® has been used successfully in humans to rescue vision threatened by angiogenic invasion of the macula (retina) when other anti-angiogenic drugs failed. This provides evidence that Longevinex® exerts biological activity in the human retina and passes through the blood-ocular barrier. There is no need for nano-encapsulation.
4. Longevinex® has been demonstrated to abolish diminished flow-mediated dilatation in humans (the first sign of arterial aging), double the effect of plain resveratrol.
5. In an animal model of induced heart attack, Longevine®x reduced damage to heart muscle in a superior manner to plain resveratrol and restored the microRNA profile to pre-heart attack expression profiles in a study conducted by NIH researchers. Longevinex has shown to differentiate microRNA involved in anti-angiogenesis 6-fold better than plain resveratrol. (See reference #5 below)
6. The claim that resveratrol is not biologically available is a myth. Resveratrol liver metabolites have recently been demonstrated to exhibit biological activity in two studies published in May and June of this year.

Bill Sardi, managing partner

Resveratrol Partners LLC, dba LONGEVINEX®

Then Sardi directs his consternation towards researchers writing in Experimental Gerontology (early online article #18) who call for studies to compare the biological effects of resveratrol versus a calorie restricted diet, the latter known to double the lifespan of laboratory animals.

Sardi’s retort is as follows:

July 20., 2013
To: Yan Y. Lam, Courtney M. Peterson, Eric Ravussin
John S McIlhenny Skeletal Muscle Physiology Laboratory,
Pennington Biomedical Research Center Baton Rouge, LA

It is difficult to conceive how your review paper regarding resveratrol versus calorie restriction (CR) could have overlooked a prior report by Barger, Weindruch and Prolla, noted aging researchers, whom your report cites, but fails to note this same research team conducted another study unmentioned in your report.

That global gene array study, published in Experimental Gerontology in 2008, found that a 12-week course of CR significantly differentiated 198 genes, resveratrol 225 genes, and a proprietary matrix of small molecules 1711 genes (9-fold more). Furthermore, life-long CR differentiates 831 genes whereas short-term use of the resveratrol-based matrix activated 677 of those 831 in the same direction as CR. It is stupefying how your paper overlooked reporting on a study that reveals a commercially available resveratrol-based matrix is the closest to molecularly mimicking the epigenetic effects of CR on record.

Bill Sardi, managing partner,

Resveratrol Partners LLC, dba LONGEVINEX

“Longevinex® has produced unprecedented scientific achievements, far greater than those generated by a developmental drug company that sold for $725 million.  Need I say more?” asks Sardi.   ®2013 Bill Sardi, ResveratrolNews.com